IASO Bio Secures Singapore Approval for FUCASO CAR-T
SHANGHAI, NANJING, China, and PLEASANTON, Calif., June 18, 2026 IASO Bio has achieved a major international regulatory milestone with...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology oncology innovation Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
SHANGHAI, NANJING, China, and PLEASANTON, Calif., June 18, 2026 IASO Bio has achieved a major international regulatory milestone with...
INDIANAPOLIS, Ind., June 18, 2026 Elanco Animal Health Incorporated has announced plans to establish Elanco Ventures, a dedicated corporate...
SINGAPORE and SEOUL, South Korea, June 17, 2026 D&D Pharmatech and HistoIndex have announced encouraging new findings from an...
BOULDER, Colo., June 16, 2026 Edgewise Therapeutics has announced positive top-line results from the 12-week Phase 2 CIRRUS-HCM trial...
FRIENDSWOOD, Texas, June 16, 2026 Castle Biosciences has announced that its TissueCypher® Barrett’s Esophagus Test has surpassed 100,000 clinical...
SALT LAKE CITY, May 26, 2026 Myriad Genetics announced the launch of Prolaris® + AI, the first prostate cancer...
BASEL, Switzerland – May 7, 2026 Roche announced it has entered into a definitive merger agreement to acquire PathAI,...
United States | December 23, 2025 — Fulgent Genetics has entered into a definitive agreement to acquire specific assets...
